Silico Insights of Woburn, Mass., and Ashni Naturaceuticals of Salt Lake City, Utah, are collaborating to identify regulatory and post-translational pathways from genomics and proteomics data using Silico Insights’ iSight bioinformatics platform.
Ashni will use its genomic BioPrinting technology to characterize anti-inflammatory action of mixtures of natural compounds and Silico Insights will apply an expanded version of the iSight platform to establish dependencies and pathways from the research data generated by Ashni.
Nandan Padukone, president of Silico Insights, said that the two companies have filed a joint patent application on the pathway identification methodology, which combines Silico Insights’ bioinformatics platform and Ashni’s proteomics knowledge.
Financial terms of the agreement were not disclosed.
Ashni intends to build compound libraries by combining genomic and proteomic research with the study of natural compounds.
The two companies are still working out the details of how they intend to distribute the resulting data. “We haven’t finalized what the final product will be,” Padukone said.
Padukone said one possibility would be third-party users who could use the analytical platform to identify pathways that could lead to drug targets. The companies are also considering using Ashni’s data and the iSight platform to build proprietary products. “That’s always a possibility, but we haven’t fully defined that route yet,” he said.
Padukone said that Silico Insights has been approached by a number of post-genomic tool and data providers interested in using the company’s technology to analyze complex data.